Interim report Q2/2022: Improved sales give confidence for the future

The full year-end report is available on: www.enzymatica.com/investors/financial-reports  The full year-end report is available on:www.enzymatica.com/investors/financial-reports   This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at08:30 a.m. CETon19 July 2022. For more information, please contact: ...

The full year-end report is available on: www.enzymatica.com/investors/financial-reports 

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET
on 19 July 2022.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: [email protected] 

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: [email protected]

Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: [email protected].

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/interim-report-q2-2022--improved-sales-give-confidence-for-the-future,c3602965

The following files are available for download: